In Q4 2025, SI-BONE generated worldwide revenue of 56350000, delivered positive adjusted EBITDA of 5150000, narrowed its net loss to 1648000, and produced positive free cash flow, ending the quarter with strong cash reserves.

SI-BONE delivered strong revenue growth and positive adjusted EBITDA in Q3 2025, along with a reduced net loss, improved gross margin, and growth across both U.S. and international markets.

SI-BONE delivered a robust second quarter in 2025, with worldwide revenue increasing by 21.7% to $48.6 million. The company achieved positive Adjusted EBITDA of $1.0 million and generated $1.1 million in net cash, demonstrating strong operational performance and disciplined execution. Net loss improved by 31.2% to $6.2 million.

SI-BONE, Inc. announced a strong start to 2025, with worldwide revenue increasing by 24.9% to $47.3 million and U.S. revenue growing by 26.6% to $44.8 million. The company achieved positive adjusted EBITDA of $0.5 million, a significant improvement from a loss in the prior year, and reduced net cash usage by 31.7%.

SI-BONE, Inc. delivered a strong performance in Q4 2024, with worldwide revenue reaching $49.0 million, a 26% increase year-over-year, and achieving positive adjusted EBITDA of $1.9 million, marking a significant improvement from the previous year.

SI-BONE reported a strong Q3 2024 with worldwide revenue of $40.3 million, representing a growth of approximately 19%. The company significantly improved its financial performance, reducing its net loss by approximately 34% and its Adjusted EBITDA loss by approximately 94%. They expect to achieve positive Adjusted EBITDA in the fourth quarter of 2024.

SI-BONE, Inc. reported strong Q2 2024 financial results, with worldwide revenue of $40.0 million, representing a growth of approximately 20%. The company's net loss improved by approximately 20%, and they ended the quarter with $151.5 million in cash and equivalents. They increased 2024 revenue guidance to $165 million - $167 million and expects to achieve positive Adjusted EBITDA in Fourth Quarter 2024.

SI-BONE, Inc. reported a worldwide revenue of $37.9 million, a 16% increase compared to the prior year period. The company updated its 2024 worldwide revenue guidance to be in the range of $164 million to $166 million.

SI-BONE reported a 22% increase in worldwide revenue for Q4 2023, driven by a 22% increase in U.S. revenue. The company's gross margin was 74%, impacted by procedure and product mix and an excess inventory reserve. Net loss improved slightly to $11.0 million, and adjusted EBITDA loss decreased to $4.8 million.

SI-BONE, Inc. reported record worldwide revenue of $34.0 million for Q3 2023, representing approximately 29% growth over the corresponding period in 2022. The company's annual guidance was increased to $136 million - $137 million, implying annual growth of 28%-29%.

SI-BONE, Inc. reported a strong second quarter with record worldwide revenue of $33.3 million, representing a 30% increase year-over-year. U.S. revenue also reached a record $31.2 million, a 31% increase year-over-year. The company's operating loss improved by 33% and net loss improved by 39%.

SI-BONE, Inc. reported record worldwide revenue of $32.7 million for Q1 2023, a 46% increase year-over-year. U.S. revenue also hit a record at $30.5 million, a 50% increase. The company's annual revenue guidance was increased to $128 million - $131 million, reflecting anticipated growth of 20%-23%.

SI-BONE, Inc. reported a 27% increase in worldwide revenue for Q4 2022, reaching $32.0 million. U.S. revenue increased by 28% to $30.0 million. The company's net loss was $11.2 million, or $0.32 per diluted share, and the adjusted EBITDA loss improved by 54% to $4.2 million.

SI-BONE reported a record worldwide revenue of $26.4 million for Q3 2022, representing a 19% increase over the corresponding period in 2021. The company's U.S. revenue also hit a record of $24.6 million, a 21% increase year-over-year. The gross margin was 84% for the third quarter 2022.

SI-BONE, Inc. reported record worldwide revenue of $25.6 million for the second quarter 2022, representing approximately 15% increase over the corresponding period in 2021. The company's gross margin was 86% for the second quarter 2022.

SI-BONE, Inc. reported a 10% increase in worldwide revenue, reaching $22.4 million for the first quarter of 2022. U.S. revenue increased by 9% to $20.4 million, and the gross margin was 87%. The company's operating loss was $16.9 million, and the net loss was $17.4 million, or $0.52 per diluted share.

SI-BONE, Inc. reported a 14% increase in worldwide revenue for Q4 2021, reaching $25.2 million, and a gross margin of 87%. The company's operating loss was $13.9 million, and net loss was $14.5 million, or $0.43 per diluted share.

SI-BONE reported a record worldwide revenue of $22.3 million for Q3 2021, representing a 9% increase over the corresponding period in 2020. The company's gross margin was 89% for the third quarter 2021. They are updating the full year 2021 total revenue guidance to be approximately $89 million to $90 million, representing growth of 21% to 23% compared to full year 2020.

SI-BONE, Inc. reported a record worldwide revenue of $22.2 million for Q2 2021, a 58% increase compared to Q2 2020. The company's U.S. revenue increased by 53% to $20.2 million. The company is maintaining its full year 2021 total revenue guidance to be approximately $92 million to $94 million.

SI-BONE, Inc. reported a 22% increase in worldwide revenue, reaching $20.4 million for the first quarter of 2021, compared to $16.8 million in the corresponding period in 2020. U.S. revenue increased by 23% to $18.8 million. The company's net loss was $12.2 million, or $0.37 per diluted share.

SI-BONE, Inc. reported a 12% increase in worldwide revenue for the fourth quarter of 2020, reaching $22.1 million. The company's U.S. revenue also increased by 12% to $20.7 million. Despite the lingering effects of the COVID-19 pandemic, SI-BONE sees strong underlying momentum in its business and provides full year 2021 revenue guidance of $92 million to $94 million, or 25% to 28% growth.

SI-BONE reported a 26% increase in worldwide revenue, reaching $20.4 million for Q3 2020, with U.S. revenue up by 27% to $18.9 million. The company's operating loss decreased to $8.7 million, and net loss improved to $9.5 million, or $0.33 per diluted share.

SI-BONE, Inc. reported a decrease in revenue for the second quarter of 2020, primarily due to the impact of the COVID-19 pandemic on case volumes. Revenue was $14.0 million, a 14% decrease compared to the previous year. The company completed debt refinancing and obtained positive coverage by Aetna.

SI-BONE, Inc. reported a 12% increase in revenue to $16.8 million for Q1 2020, with U.S. revenue up 14% to $15.3 million. The company's operating loss was $11.9 million, and net loss was $12.8 million, or $0.47 per diluted share.

SI-BONE reported a 27% increase in worldwide revenue, reaching $19.8 million for Q4 2019. U.S. revenue grew by 28% to $18.5 million. However, the company's operating loss widened to $8.5 million due to increased operating expenses.